Avelumab

A4DAB029 | Cancer | Approved
PDL1/CD274
G1 / IgG1
AIO Studien gGmbH Array BioPharma Chong Kun Dang Dana-Farber Cancer Institute Debiopharm eFFECTOR Therapeutics EMD Serono Forty Seven Fred Hutchinson Cancer Research Center Gachon University Gil Medical Center Hellenic Cooperative Oncology Group Hospices Civils de Lyon Johannes Gutenberg-University Mainz M. D. Anderson Cancer Center Merck KGaA National Cancer Institute (USA) National Cancer Institute Slovakia Netherlands Cancer Institute Pfizer Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Syndax Pharmaceuticals Transgene University College London University of Birmingham University of California San Diego University of Iowa Vaccinex Vanderbilt-Ingram Cancer Center VAXIMM Verastem Oncology Washington University School of Medicine
Approved
Whole mAb
BAVENCIO MSB-0010718C MSB0010718 CPF-06834635 CPF06834635
5.0-5.6
IMGT PubChem (252827393) PubChem (336908606) PubChem (347911260) PubChem (355203045) PubChem (355203157) PubChem (381127599) PubChem (472264634) PubChem (472423499) PubChem (481101526) PubChem (496735331) PubChem (498152138) PubChem (508534488) PubChem (519932891) Thera-SAbDab YAbS
Avg A4D Score
-0.586
Score Range
-0.66 to -0.51
Structures
2
Avg. A4D Score per Structure
pH at Min / Max Aggregation Propensity

Associated Structural Profiles Level 2

Structure ID Source PDB Seq. Identity Avg. A4D Score pH (Min Agg.) pH (Max Agg.) Score CDR Score non-CDR
A4DAB029_5grj_H_L 5grj 100% -0.5133 6.5 9.0 0.0018 -0.6634
A4DAB029_4nki_H_L 4nki 100% -0.6588 6.0 9.0 -0.0555 -0.7394